Ionis Pharmaceuticals, Inc. – NASDAQ:IONS

Add to watchlist

$42.48

+6.57

+18.3%

Market closed

Open in 2 days

-25.19%

month

-25.19%

quarter

-28.41%

year

Market Cap	5.68B
Enterprise value	6.37B

P/E	-19.29
EV/Sales	10.86
EV/EBITDA	-28.00
Price/Sales	9.00
Price/Book	9.22
PEG ratio	0.02
EPS	-2.66

Revenue	776.00M
EBITDA	-327.53M
Income	-384.06M
Revenue Q/Q	-8.78%
Revenue Y/Y	34.59%

Profit margin	-45.92%
Oper. margin	-69.82%
Gross margin	97.6%
EBIT margin	-69.82%
EBITDA margin	-42.21%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS): Profit margin
Jun 2023	188M	-85M	-45.21%
Sep 2023	144M	-147M	-102.08%
Dec 2023	324.50M	-9.26M	-2.85%
Mar 2024	119.49M	-142.80M	-119.5%

Ionis Pharmaceuticals Financials Estimate

Q Y

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS): Analyst Estimates
Dec 2023	324.50M	-9.26M	-2.85%
Mar 2024	119.49M	-142.80M	-119.5%
Sep 2025	170.25M	-149.88M	-88.03%
Dec 2025	198.03M	-134.32M	-67.83%

Analysts Price target
Financials & Ratios estimates

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS): Debt to assets
Jun 2023	2971000000	2.54B	85.59%
Sep 2023	2934000000	2.61B	89.26%
Dec 2023	2990072000	2.60B	87.07%
Mar 2024	2763928000	2.46B	89.27%

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS): Cash Flow
Jun 2023	-97.36M	69.51M	143.53M
Sep 2023	-109.02M	68.71M	-32.26M
Dec 2023	32.86M	-26.71M	40.72M
Mar 2024	-149.93M	76.10M	23.57M

Ionis Pharmaceuticals alternative data

Ionis Pharmaceuticals
Employees

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS): Employee count
Aug 2023	796
Sep 2023	796
Oct 2023	796
Nov 2023	796
Dec 2023	796
Jan 2024	796
Feb 2024	796
Mar 2024	927
Apr 2024	927
May 2024	927
Jun 2024	927
Jul 2024	927

Ionis Pharmaceuticals
Hedge Funds Holdings Q3 2022

80.85% -5.60%

of IONS is owned by hedge funds

305 -29

hedge funds hold IONS stock

114.64M -7.76M

shares is hold by hedge funds

IONS hedge funds holdings changes

Ionis Pharmaceuticals
Insider Trading

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	113949
Feb 2024	0	37891
Apr 2024	0	4911
May 2024	0	6000
Jun 2024	0	16000
Jul 2024	0	13637
Aug 2024	0	3081
Oct 2024	0	53
Nov 2024	0	21332
Dec 2024	5000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	23 Dec 2024	HAYDEN MICHAEL R director director	Common Stock	2,500	$36.23	$90,582
Purchase	23 Dec 2024	HAYDEN MICHAEL R director director	Common Stock	2,500	$36.2	$90,495
Sale	12 Nov 2024	SWAYZE ERIC officer: EVP Research officer: EVP Research	Common Stock	1,194	$37.92	$45,278
Sale	12 Nov 2024	MONIA BRETT P director, officer..	Common Stock	6,630	$38.05	$252,291
Sale	12 Nov 2024	MONIA BRETT P director, officer..	Common Stock	6,630	$38.05	$252,291
Sale	12 Nov 2024	LOSCALZO JOSEPH director director	Common Stock	13,508	$37.86	$511,426
Sale	16 Oct 2024	SWAYZE ERIC officer: EVP Research officer: EVP Research	Common Stock	53	$38.31	$2,031
Option	15 Oct 2024	SWAYZE ERIC officer: EVP Research officer: EVP Research	Restricted Stock Unit	125	N/A	N/A
Option	15 Oct 2024	SWAYZE ERIC officer: EVP Research officer: EVP Research	Common Stock	125	N/A	N/A
Sale	29 Aug 2024	GEARY RICHARD S officer: EVP, Chi..	Common Stock	331	$49.63	$16,428

IONS insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION Filling date: 24 Sep 2021 Issue date: 18 Aug 2022	24 Sep 2021	18 Aug 2022
Application	Application METHODS AND COMPOSITIONS FOR INHIBITING PMP22 EXPRESSION Filling date: 4 Oct 2021 Issue date: 11 Aug 2022	4 Oct 2021	11 Aug 2022
Application	Application ANGIOTENSIN II TYPE 1 RECEPTOR TARGETED OLIGONUCLEOTIDES AND USES THEREOF Filling date: 18 May 2020 Issue date: 4 Aug 2022	18 May 2020	4 Aug 2022
Application	Application Compositions for Modulating Ataxin 2 Expression Filling date: 4 Aug 2021 Issue date: 23 Jun 2022	4 Aug 2021	23 Jun 2022
Application	Application COMPOUNDS AND METHODS FOR REDUCING KCNT1 EXPRESSION Filling date: 13 Mar 2020 Issue date: 9 Jun 2022	13 Mar 2020	9 Jun 2022
Grant	Grant Utility: Modulators of diacyglycerol acyltransferase 2 (DGAT2) Filling date: 28 Jun 2019 Issue date: 26 Apr 2022	28 Jun 2019	26 Apr 2022
Application	Application MODULATION OF GYS1 EXPRESSION Filling date: 23 Dec 2021 Issue date: 14 Apr 2022	23 Dec 2021	14 Apr 2022
Grant	Grant Utility: Compounds and methods for modulating SMN2 Filling date: 24 Jun 2021 Issue date: 12 Apr 2022	24 Jun 2021	12 Apr 2022
Application	Application Compounds and Methods for Use in Dystrophin Transcript Filling date: 18 Nov 2020 Issue date: 17 Mar 2022	18 Nov 2020	17 Mar 2022
Application	Application COMPOUNDS AND METHODS FOR MODULATION OF SMN2 Filling date: 18 Dec 2020 Issue date: 10 Mar 2022	18 Dec 2020	10 Mar 2022

Ionis Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 7 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 21 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 2 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 9 Aug 2023	Q2 2023 Earnings Call Transcript

IONS earnings call transcripts

Ionis Pharmaceuticals
Executives

Insider	Age	Compensation
Dr. Brett P. Monia Ph.D. (1961) Founder, Chief Executive Officer & Director	64	$1,340,000
Dr. Stanley T. Crooke (1945) Scientific Advisor	80	$1,310,000
Ms. B. Lynne Parshall Esq., J.D. (1954) Senior Strategic Advisor & Director	71	$1,030,000
Dr. Richard S. Geary (1958) Executive Vice President & Chief Devel. Officer	67	$868,910
Ms. Elizabeth L. Hougen (1962) Executive Vice President & Chief Financial Officer	63	$862,130
Mr. Patrick R. O'Neil Esq. (1974) Executive Vice President, Chief Legal Officer & Gen. Counsel	51	$822,930

Ionis Pharmaceuticals
Latest News

Wednesday, 11 December 2024
10:55	How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91%	zacks.com
Wednesday, 27 November 2024
13:01	Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock?	zacks.com
Monday, 18 November 2024
10:37	Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks	zacks.com
Thursday, 7 November 2024
16:01	Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus	zacks.com
07:05	Ionis to present at upcoming investor conferences	prnewswire.com
Wednesday, 6 November 2024
14:35	Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript	seekingalpha.com
10:35	Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics	zacks.com
09:10	Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
07:01	Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome	prnewswire.com
07:00	Ionis reports third quarter 2024 financial results	prnewswire.com
Monday, 4 November 2024
10:22	Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS	zacks.com
09:44	Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE	prnewswire.com
Wednesday, 30 October 2024
11:06	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?	zacks.com
Wednesday, 23 October 2024
16:25	Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling	seekingalpha.com
07:05	Ionis to hold third quarter 2024 financial results webcast	prnewswire.com
Monday, 21 October 2024
02:59	AstraZenca drug for nerve damage given EU Green light	proactiveinvestors.co.uk
02:08	WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis	prnewswire.com
Thursday, 3 October 2024
07:00	New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting	prnewswire.com
Wednesday, 2 October 2024
10:11	IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag	zacks.com
Tuesday, 1 October 2024
07:00	Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease	prnewswire.com
Wednesday, 11 September 2024
13:26	Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering	zacks.com
Tuesday, 10 September 2024
08:32	Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session	benzinga.com
Monday, 9 September 2024
21:10	Ionis announces pricing of $500.3 million public offering	prnewswire.com
16:20	Ionis announces proposed public offering of common stock	prnewswire.com
Wednesday, 28 August 2024
07:05	Ionis to present at upcoming investor conferences	prnewswire.com
Thursday, 15 August 2024
10:16	Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?	zacks.com
Sunday, 11 August 2024
06:51	Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value	seekingalpha.com
Tuesday, 6 August 2024
05:05	The Zacks Analyst Blog AstraZeneca, Ionis and Sanofi	zacks.com
Friday, 2 August 2024
10:56	Ionis (IONS) Q2 Earnings and Revenues Beat, Stock Rises	zacks.com
Thursday, 1 August 2024
16:52	Ionis Pharmaceuticals, Inc. (IONS) Q2 2024 Earnings Call Transcript	seekingalpha.com

Ideas & Opinions

Seeking Alpha 13 Jul 2025

Why Novartis Is Still A 'Buy' After 15% Surge
Seeking Alpha 29 Jun 2025

Ionis: After Years Of Investment, The Wholly-Owned Payoff Is In Sight
Seeking Alpha 22 Apr 2025

Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade)
Seeking Alpha 18 Apr 2025

89bio: A Buy With Strong Market Opportunity In MASH And SHTG
Seeking Alpha 23 Dec 2024

Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval
Seeking Alpha 24 Jun 2024

HELIOS-B Shines Bright And Gives Alnylam Pharmaceuticals Another Blockbuster
Seeking Alpha 3 Jun 2024

Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation
Seeking Alpha 28 May 2024

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism
Seeking Alpha 29 Dec 2023

3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations
Seeking Alpha 4 Dec 2023

Ionis Pharmaceuticals: Pioneering Precision Medicine

Frequently Asked Questions (FAQ)

What's the price of Ionis Pharmaceuticals stock today?

One share of Ionis Pharmaceuticals stock can currently be purchased for approximately $42.48.
When is Ionis Pharmaceuticals's next earnings date?

Unfortunately, Ionis Pharmaceuticals's (IONS) next earnings date is currently unknown.
Does Ionis Pharmaceuticals pay dividends?

No, Ionis Pharmaceuticals does not pay dividends.
How much money does Ionis Pharmaceuticals make?

Ionis Pharmaceuticals has a market capitalization of 5.68B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 34.18% to 787.65M US dollars.
What is Ionis Pharmaceuticals's stock symbol?

Ionis Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "IONS".
What is Ionis Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Ionis Pharmaceuticals?

Shares of Ionis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Ionis Pharmaceuticals's key executives?
Ionis Pharmaceuticals's management team includes the following people:
- Dr. Brett P. Monia Ph.D. Founder, Chief Executive Officer & Director(age: 64, pay: $1,340,000)
- Dr. Stanley T. Crooke Scientific Advisor(age: 80, pay: $1,310,000)
- Ms. B. Lynne Parshall Esq., J.D. Senior Strategic Advisor & Director(age: 71, pay: $1,030,000)
- Dr. Richard S. Geary Executive Vice President & Chief Devel. Officer(age: 67, pay: $868,910)
- Ms. Elizabeth L. Hougen Executive Vice President & Chief Financial Officer(age: 63, pay: $862,130)
- Mr. Patrick R. O'Neil Esq. Executive Vice President, Chief Legal Officer & Gen. Counsel(age: 51, pay: $822,930)
Is Ionis Pharmaceuticals founder-led company?

Yes, Ionis Pharmaceuticals is a company led by its founder Dr. Brett P. Monia Ph.D..
How many employees does Ionis Pharmaceuticals have?

As Jul 2024, Ionis Pharmaceuticals employs 927 workers.
When Ionis Pharmaceuticals went public?

Ionis Pharmaceuticals, Inc. is publicly traded company for more then 34 years since IPO on 17 May 1991.
What is Ionis Pharmaceuticals's official website?

The official website for Ionis Pharmaceuticals is ionispharma.com.
Where are Ionis Pharmaceuticals's headquarters?

Ionis Pharmaceuticals is headquartered at 2855 Gazelle Court, Carlsbad, CA.
How can i contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals's mailing address is 2855 Gazelle Court, Carlsbad, CA and company can be reached via phone at +7 609319200.

Ionis Pharmaceuticals, Inc.

ionispharma.com

Exchange:

NASDAQ

Full time employees:

927

Industry:

Biotechnology

Sector:

Healthcare

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

+7 609319200

2855 Gazelle Court
Carlsbad, CA 92010

CIK: 0000874015
ISIN: US4622221004
CUSIP: 462222100